Can nandrolone add to the effect of hormonal replacement therapy in postmenopausal osteoporosis?
Thirty-six women with postmenopausal osteoporosis (31 of them with at least one non-traumatic vertebral compression fracture) were matched pair-wise as to age, years since menopause and body mass index and randomized to receive either cyclical estrogen-progestagen replacement treatment (group 1) or the same treatment plus nandrolone decanoate (group 2). During the first year of treatment in both groups the forearm BMC (SPA) rose proximally and distally 2-3%. Over 2 years the increments of forearm BMC in both groups were up to 4.5%. Lumbar BMC (DPA) rose in both groups nearly 10% over the first year and 12-12.5% over 2 years. The cancellous bone density of L3 (QCT) showed in 6 months an increase of 21% in group 1 and 29% in group 2 to subsequently stay at that level. All these changes from the basal levels were highly significant but there were no significant differences between the two groups. These two conclusions were also drawn with regard to the induced fall of serum alkaline phosphatase (-23%), osteocalcin (-35% to -44%) and procollagen I (-15% to -22%) and of the fasting urinary hydroxyproline (-33% to -36%). No significant increase in the number of newly deformed vertebrae occurred in 2 years.
Birkenhäger
J C
JC
Department of Medicine (III), University Hospital Dijkzigt, Erasmus University, Rotterdam, Netherlands.
Erdtsieck
R J
RJ
Zeelenberg
J
J
van Kuik
C
C
van Veen
L C
LC
Birkenhäger-Frenkel
D H
DH
Luiken
G P
GP
Kooy
P P
PP
Gerritsma
E J
EJ
Mulder
P
P
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density; D002118:Calcium / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008875:Middle Aged; D009277:Nandrolone / Q000009:adverse effects / Q000627:therapeutic use*; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D016037:Single-Blind Method; D014832:Voice Disorders / Q000139:chemically induced
D008076:Cholesterol, HDL; D015675:Osteocalcin; D004958:Estradiol; D009277:Nandrolone; D002784:Cholesterol; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium